Zenith Healthcare

Zenith Healthcare EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Zenith Healthcare (530665.BO) as of Oct 19, 2026 is -18.32. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 53.55 — a change of -134.21% (lower).

EV/FCF

-18.32

YoY

-134.21%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Zenith Healthcare is 2026 -18.32 . EV/FCF (Enterprise Value to Free Cash Flow) of Zenith Healthcare was 2025 53.55 . It decreases by -134.21% lower compared to the previous year.

The Zenith Healthcare EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-157.23 INR
Jan 1, 2020
10.83 INR
Jan 1, 2021
-10.54 INR
Jan 1, 2022
15.12 INR
Jan 1, 2023
-17.55 INR
Jan 1, 2024
9.60 INR
Jan 1, 2025
53.55 INR
Jan 1, 2026
-18.32 INR
The Zenith Healthcare EV/FCF history
YEAREV/FCFYoY
-18.32-134.21%
53.55+457.81%
9.60-154.69%
-17.55-216.06%
15.12-243.44%
-10.54-197.36%
10.83-106.89%
-157.23-326.60%
69.39-102.19%
-3,171.68-2,183.09%
152.26-250.26%
-101.33+386.64%
-20.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenith Healthcare Stock analysis

What does Zenith Healthcare do? Zenith Healthcare Ltd is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. The firm engages in the manufacture of pharmaceutical formulations, producing products in various dosage forms including tablets, capsules, oral liquids, and injections. Zenith Healthcare offers its products across a diverse range of therapeutic segments, covering areas such as antibiotics and anti-infectives, gastrointestinal tract disorders, analgesic and anti-inflammatory treatments, cardiovascular system conditions, respiratory issues, ophthalmology, biotechnical products, oncology, anti-retroviral therapies, central nervous system disorders, nutrition, genito-urinary system ailments, and skin conditions. Specific products within the antibiotics and anti-infective category include Roxythromycin Tablets, Ciprofloxacin Tablets, Azithromycine Dihydrate Suspension, and Azithromycin Oral Suspension. In the gastrointestinal segment, the company provides Ranitidine Hydrochloride Tablets. For the cardiovascular system, Lisinopril Tablets are part of its portfolio. The analgesic category features Paracetamol and Aceclofenac Tablets. Additionally, the company offers contract manufacturing services for all dosage forms, catering to broader industry needs. Zenith Healthcare Ltd went public on April 27, 1995, with the ticker symbol 530665.BO and ISIN INE812B01026. The company's official website is https://www.zenithhealthcare.com/. As a player in the health care sector, specifically within the pharmaceuticals industry, Zenith Healthcare Ltd contributes to the availability of essential medicines across multiple therapeutic areas. Its manufacturing capabilities and wide product range allow it to serve various market demands, from generic formulations to specialized treatments. The company's presence in Ahmedabad positions it within a significant industrial hub in India, facilitating its operational and logistical activities. Through its comprehensive product portfolio and contract manufacturing services, Zenith Healthcare Ltd aims to meet the healthcare needs of patients and partners alike, maintaining a focus on quality and efficacy in its pharmaceutical offerings. The company's public listing since 1995 reflects its established presence in the financial markets, providing investors with exposure to the Indian pharmaceutical sector. Its diverse therapeutic coverage underscores its commitment to addressing a broad spectrum of medical conditions, from common infections to complex chronic diseases. This strategic positioning enables Zenith Healthcare Ltd to remain competitive in the dynamic pharmaceutical landscape, adapting to evolving healthcare requirements and regulatory standards in India and potentially beyond. Zenith Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenith Healthcare stock

EV/FCF (Enterprise Value to Free Cash Flow) of Zenith Healthcare is -18.32 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Zenith Healthcare changed from 53.55 to -18.32, representing a -134.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Zenith Healthcare since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Zenith Healthcare with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zenith Healthcare

All Key Metrics — Zenith Healthcare